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Small patella syndrome: New clinical and molecular insights
into a consistent phenotype
To the Editor:
Small patella syndrome (SPS, OMIM#147891) is a rare autosomal
dominant disorder characterized by patellar agenesis or hypoplasia,
abnormal ossification of the ischio-pubic junction, and feet abnormal-
ities. This condition is caused by haploinsufficiency of TBX4,1 encod-
ing a T-box transcription factor involved in lower limb development
and airway branching.2,3 Ten different TBX4 mutations have been
reported so far in SPS patients.1,4 In addition, 6 mutations were asso-
ciated with childhood-onset pulmonary arterial hypertension (PAH),
in patients who also had SPS features after clinical reassessment.4
Loss of Tbx4 at early stages of limb development in mice (E.9.5-10.5)
results in hypoplastic fibula, femur and pelvis and thin anterior hin-
dlimb digits.2 Two hindlimb-specific Tbx4 enhancers (HLEA and
HLEB) have been described in mice.5 Pitx1, directly involved in the
hindlimb-type morphology, is required to maintain normal levels of
Tbx4 expression through these regulatory elements.5
Patients from 10 unrelated families with features suggestive of
SPS were recruited from several clinical genetics departments
(Table 1). They were referred mostly for recurrent knee subluxations
and presented with characteristic skeletal features. The patellar
defects were bilateral, the left side being slightly more affected. Diag-
nosis of SPS has been established a posteriori in 9 affected relatives
among 6 families, raising the number of patients to 19.
Our study was performed using the Declaration of Helsinki proto-
col. Written informed consents were obtained from the patients. We
performed Sanger sequencing of all TBX4 coding exons and their flank-
ing intronic regions (NM_018488.2, Hg19), and rearrangement screen-
ing by multiplex ligation-dependent probe amplification (P390-A1,
MRC-Holland). In seven families we found TBX4 anomalies predicted
to cause loss-of-function or haploinsufficiency, confirming the clinical
diagnosis of SPS. Of those, four were newly described (Table 1) and
reported into LOVD Database. In three mutation-negative families, we
performed Sanger sequencing of ortholog HLEA (chr17:59,521,403-
59,521,530[Hg19]) and HLEB (chr17:59,611,720-59,612,278[Hg19])
regulatory regions identified in mouse, 180K array-CGH (comparative
genomic hybridization) and the high-throughput targeted sequencing
of 124 genes involved in limb development. Those additional analyses
failed to identify any pathogenic variations.
SPS shows a consistent skeletal phenotype with constant patella
and pelvic defects. Feet abnormalities are very frequent but may be
mild and therefore overlooked. Our study raises some new features
with incomplete penetrance: developmental dysplasia of the hip
(DDH), spine deformities and dental issues.
DDH, observed in 4 probands, has not been described so far.
Two patients needed surgical repair after orthopaedic treatment fail-
ure. We assume that pelvic ossification abnormalities could affect the
morphology of the acetabular region and predispose to DDH.
Spine deformities were major findings in 2 probands (severe scoli-
osis in family 3 and kyphosis due to fused 8th-9th thoracic vertebrae
and lombar-like morphology of S1 in family 8) and therefore defi-
nitely a condition to survey in SPS. Paediatric follow-up did not
reveal any DDH or spinal deformities in the other probands.
Finally, dental examinations revealed numerous caries of primary
and permanent dentition and/or permanent teeth eruption delay in four
patients from two different families whereas none of their non-
mutated relatives were affected. It is still unclear if this may be
related or not to SPS.
Besides, only one proband suffers from idiopathic PAH, confirming
its incomplete penetrance in SPS. She presented with exercise intoler-
ance with cyanosis and syncope due to pulmonary hypertensive crises
at 4 year old. Interestingly, the 3 individuals from family 3 are not
affected with PAH while they share the same mutation with a previ-
ously reported SPS patient with PAH (patient 5 in Ref. 4). None of the
other affected patients had clinical symptoms of childhood-onset PAH.
Studies on larger cohorts are required to understand the full range of
phenotypes and their penetrance, resulting from TBX4 mutations.
The phenotypes observed in the mutation-negative patients
appeared similar to those of the mutated patients. The SPS clinical
picture appears consistent and easily recognizable among differential
diagnoses. However, we sequenced a panel of 124 genes involved in
limb development, revealing no pathogenic variation. Disruption of
cis-regulatory modules appears to be a growing cause of limb malfor-
mations. We did not find any pathogenic sequence variation in the
two TBX4 enhancers. However, previous data in mice showed addi-
tional Pitx1 binding sites at the Tbx4 locus suggesting that additional
regulatory elements remain to be identified.5
Further explorations by high-throughput sequencing are required in
the molecular delineation of SPS to look for TBX4 deep intronic and regu-
latory regions, complex rearrangements or variants in other candidate
genes.
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